NUTEX Investments's EBIT per Share for the
six
months ended in Dec. 2025 was Ft-1.48.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was Ft-0.48.
During the past 3 years, the average EBIT per Share Growth Rate was -90.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -36.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 20.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for NUTEX Investments's EBIT per Share or its related term are showing as below:
BUD:NUTEX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -90.4 Med: 30.45 Max: 61.9
Current: -90.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NUTEX Investments was 61.90% per year. The lowest was -90.40% per year. And the median was 30.45% per year.
BUD:NUTEX's 3-Year EBIT Growth Rate is ranked worse than 98.52% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs BUD:NUTEX: -90.40
NUTEX Investments (BUD:NUTEX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
NUTEX Investments EBIT per Share Related Terms
NUTEX Investments EBIT per Share Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Ft-0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUTEX Investments (BUD:NUTEX) has a EBIT per Share of Ft-0.48 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NUTEX Investments and its competitors. According to the industry distribution chart, NUTEX Investments ranks #798 out of 810 companies in the Drug Manufacturers industry, placing it in the top 98.5%.
Is NUTEX Investments' EBIT per Share too high?
NUTEX Investments' current EBIT per Share is Ft-0.48. Based on the distribution chart, NUTEX Investments ranks #798 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, NUTEX Investments has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #798 out of 810 companies for EBIT per Share. This places NUTEX Investments in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current EBIT per Share is Ft-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft12.70 — trading 8% below its estimated fair value. The current EBIT per Share is Ft-0.48. NUTEX Investments' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current EBIT per Share is Ft-0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft12.70 is trading 8% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
EBIT per Share: Ft-0.48
GF Value™: Ft13.80 vs. price of Ft12.70 (8% below fair value)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
52GF Score
Get the complete analysis for BUD:NUTEX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
